Applied Finance Capital Management LLC Has $12.36 Million Holdings in CVS Health Corporation $CVS

Applied Finance Capital Management LLC lessened its holdings in shares of CVS Health Corporation (NYSE:CVS) by 15.5% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 155,748 shares of the pharmacy operator’s stock after selling 28,496 shares during the period. Applied Finance Capital Management LLC’s holdings in CVS Health were worth $12,360,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently made changes to their positions in CVS. Wellington Management Group LLP raised its stake in CVS Health by 391.6% during the third quarter. Wellington Management Group LLP now owns 6,330,717 shares of the pharmacy operator’s stock worth $477,273,000 after buying an additional 5,042,816 shares during the last quarter. Amundi raised its stake in CVS Health by 95.3% during the third quarter. Amundi now owns 7,453,980 shares of the pharmacy operator’s stock worth $572,665,000 after buying an additional 3,637,943 shares during the last quarter. Capital Research Global Investors raised its stake in CVS Health by 24.5% during the third quarter. Capital Research Global Investors now owns 11,469,250 shares of the pharmacy operator’s stock worth $864,667,000 after buying an additional 2,253,531 shares during the last quarter. Arrowstreet Capital Limited Partnership raised its stake in CVS Health by 70.5% during the third quarter. Arrowstreet Capital Limited Partnership now owns 5,294,134 shares of the pharmacy operator’s stock worth $399,125,000 after buying an additional 2,188,307 shares during the last quarter. Finally, Hamlin Capital Management LLC acquired a new stake in CVS Health in the fourth quarter worth $160,844,000. Institutional investors and hedge funds own 80.66% of the company’s stock.

CVS Health Stock Performance

Shares of CVS stock opened at $95.95 on Friday. The firm has a market cap of $122.42 billion, a price-to-earnings ratio of 42.27, a P/E/G ratio of 0.95 and a beta of 0.60. The company has a debt-to-equity ratio of 0.78, a quick ratio of 0.66 and a current ratio of 0.87. CVS Health Corporation has a 52 week low of $58.50 and a 52 week high of $98.43. The firm’s 50-day simple moving average is $78.71 and its two-hundred day simple moving average is $78.59.

CVS Health (NYSE:CVS) last posted its quarterly earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.21 by $0.36. CVS Health had a net margin of 0.72% and a return on equity of 11.88%. The company had revenue of $100.43 billion for the quarter, compared to analyst estimates of $94.99 billion. During the same quarter in the previous year, the firm posted $2.25 earnings per share. The company’s quarterly revenue was up 6.2% compared to the same quarter last year. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. As a group, equities analysts forecast that CVS Health Corporation will post 7.44 earnings per share for the current year.

CVS Health Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, May 4th. Stockholders of record on Thursday, April 23rd were paid a $0.665 dividend. The ex-dividend date of this dividend was Thursday, April 23rd. This represents a $2.66 dividend on an annualized basis and a dividend yield of 2.8%. CVS Health’s dividend payout ratio is 117.18%.

Insider Activity

In other news, EVP Tilak Mandadi sold 69,551 shares of the company’s stock in a transaction on Friday, May 8th. The shares were sold at an average price of $89.58, for a total value of $6,230,378.58. Following the completion of the sale, the executive vice president owned 10,133 shares of the company’s stock, valued at approximately $907,714.14. This represents a 87.28% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.85% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on CVS shares. Truist Financial raised their price target on shares of CVS Health from $98.00 to $102.00 and gave the stock a “buy” rating in a report on Thursday, May 7th. Sanford C. Bernstein raised their price target on shares of CVS Health from $94.00 to $106.00 and gave the stock an “outperform” rating in a report on Tuesday. Wall Street Zen upgraded shares of CVS Health from a “hold” rating to a “buy” rating in a report on Saturday, May 9th. Morgan Stanley raised their price target on shares of CVS Health from $93.00 to $106.00 and gave the stock an “overweight” rating in a report on Thursday. Finally, Wolfe Research reduced their price target on shares of CVS Health from $100.00 to $97.00 and set an “outperform” rating for the company in a report on Monday, March 2nd. Twenty-two investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $98.08.

More CVS Health News

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Morgan Stanley raised its price target on CVS Health and kept an overweight rating, signaling confidence in further upside after the company’s stronger-than-expected quarterly results. Morgan Stanley Issues Positive Forecast for CVS Health (NYSE:CVS) Stock Price
• Positive Sentiment: Argus also lifted its outlook for CVS Health, adding to the wave of analyst support that may be helping shares move higher. Argus Issues Positive Forecast for CVS Health (NYSE:CVS) Stock Price
• Positive Sentiment: CVS reported solid Q1 2026 earnings recently, beating estimates on both revenue and adjusted EPS, which continues to drive investor optimism about execution and valuation. Here is Why CVS Health (CVS) is One of the Cheap Stocks to Buy For the Next 10 Years
• Positive Sentiment: CVS and WGU launched an online pre-pharmacy degree program to help build a stronger pharmacist pipeline, a move that could support long-term staffing and service growth. CVS Health® and WGU launch online pre-pharmacy degree program for future pharmacists nationwide
• Neutral Sentiment: CVS advanced its portfolio reset by selling Omnicare after bankruptcy court approval, which simplifies the business and removes an underperforming unit, but also confirms ongoing restructuring. CVS Refocuses On Core Health Platform With Omnicare Sale And Drone Rollout
• Neutral Sentiment: CVS also highlighted community and brand-building initiatives in Rhode Island, including its economic impact report and expanded WIC acceptance, which are positive for reputation but less likely to move the stock on their own. CVS Health’s Annual Impact in Rhode Island

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.